CR20190299A - Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de transtornos respiratorios - Google Patents
Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de transtornos respiratoriosInfo
- Publication number
- CR20190299A CR20190299A CR20190299A CR20190299A CR20190299A CR 20190299 A CR20190299 A CR 20190299A CR 20190299 A CR20190299 A CR 20190299A CR 20190299 A CR20190299 A CR 20190299A CR 20190299 A CR20190299 A CR 20190299A
- Authority
- CR
- Costa Rica
- Prior art keywords
- task
- dosage forms
- pharmaceutical dosage
- apnea
- same
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 230000029058 respiratory gaseous exchange Effects 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 101001050878 Homo sapiens Potassium channel subfamily K member 9 Proteins 0.000 abstract 2
- 208000008784 apnea Diseases 0.000 abstract 2
- 208000003417 Central Sleep Apnea Diseases 0.000 abstract 1
- 102100024986 Potassium channel subfamily K member 9 Human genes 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16205688.1A EP3338764A1 (de) | 2016-12-21 | 2016-12-21 | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| EP17157805 | 2017-02-24 | ||
| PCT/EP2017/082542 WO2018114501A1 (de) | 2016-12-21 | 2017-12-13 | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190299A true CR20190299A (es) | 2019-09-04 |
Family
ID=60857052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190299A CR20190299A (es) | 2016-12-21 | 2017-12-13 | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de transtornos respiratorios |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20200093737A1 (es) |
| EP (1) | EP3558380A1 (es) |
| JP (1) | JP2020502215A (es) |
| KR (1) | KR20190099245A (es) |
| CN (1) | CN110290809A (es) |
| AU (1) | AU2017379245A1 (es) |
| BR (1) | BR112019012836A2 (es) |
| CA (1) | CA3047426A1 (es) |
| CL (1) | CL2019001726A1 (es) |
| CO (1) | CO2019006642A2 (es) |
| CR (1) | CR20190299A (es) |
| CU (1) | CU20190063A7 (es) |
| DO (1) | DOP2019000172A (es) |
| EC (1) | ECSP19044577A (es) |
| IL (1) | IL267503A (es) |
| JO (1) | JOP20190148A1 (es) |
| MA (1) | MA47074A (es) |
| MX (1) | MX2019007619A (es) |
| PE (1) | PE20191240A1 (es) |
| PH (1) | PH12019501458A1 (es) |
| TW (1) | TW201834653A (es) |
| UY (1) | UY37541A (es) |
| WO (1) | WO2018114501A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018536693A (ja) | 2015-12-10 | 2018-12-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| CN112585128B (zh) | 2018-06-18 | 2023-02-21 | 詹森药业有限公司 | 作为malt1抑制剂的吡唑衍生物 |
| MX2021006081A (es) * | 2018-11-27 | 2021-07-06 | Bayer Ag | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios. |
| CN115835864A (zh) * | 2020-07-01 | 2023-03-21 | 国立癌症中心 | 包含3-酮脂酰辅酶a硫解酶抑制剂以及肉碱酰基肉碱载体抑制剂的用于预防或治疗癌症的药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| KR101390239B1 (ko) * | 2006-04-27 | 2014-04-30 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｔａｓｋ-1 및 ｔａｓｋ-3 이온 채널 억제제 |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CN106977530A (zh) | 2010-07-09 | 2017-07-25 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| US9132243B2 (en) | 2010-07-23 | 2015-09-15 | Tannermedico A/S | Method of administering a substance to the throat |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| CN103877288B (zh) * | 2014-04-16 | 2016-01-20 | 广西信业生物技术有限公司 | 一种壳聚糖鼻咽生物医用膜及其制备方法 |
-
2017
- 2017-06-16 JO JOP/2019/0148A patent/JOP20190148A1/ar unknown
- 2017-12-13 CU CU2019000063A patent/CU20190063A7/es unknown
- 2017-12-13 US US16/472,116 patent/US20200093737A1/en not_active Abandoned
- 2017-12-13 EP EP17822216.2A patent/EP3558380A1/de not_active Withdrawn
- 2017-12-13 CR CR20190299A patent/CR20190299A/es unknown
- 2017-12-13 CA CA3047426A patent/CA3047426A1/en not_active Abandoned
- 2017-12-13 MX MX2019007619A patent/MX2019007619A/es unknown
- 2017-12-13 MA MA047074A patent/MA47074A/fr unknown
- 2017-12-13 JP JP2019533535A patent/JP2020502215A/ja active Pending
- 2017-12-13 WO PCT/EP2017/082542 patent/WO2018114501A1/de active Application Filing
- 2017-12-13 AU AU2017379245A patent/AU2017379245A1/en not_active Abandoned
- 2017-12-13 CN CN201780086896.1A patent/CN110290809A/zh active Pending
- 2017-12-13 KR KR1020197020701A patent/KR20190099245A/ko unknown
- 2017-12-13 BR BR112019012836A patent/BR112019012836A2/pt not_active Application Discontinuation
- 2017-12-13 PE PE2019001285A patent/PE20191240A1/es unknown
- 2017-12-19 TW TW106144527A patent/TW201834653A/zh unknown
- 2017-12-21 UY UY0001037541A patent/UY37541A/es not_active Application Discontinuation
-
2019
- 2019-06-19 DO DO2019000172A patent/DOP2019000172A/es unknown
- 2019-06-19 IL IL267503A patent/IL267503A/en unknown
- 2019-06-20 CL CL2019001726A patent/CL2019001726A1/es unknown
- 2019-06-21 EC ECSENADI201944577A patent/ECSP19044577A/es unknown
- 2019-06-21 PH PH12019501458A patent/PH12019501458A1/en unknown
- 2019-06-21 CO CONC2019/0006642A patent/CO2019006642A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200093737A1 (en) | 2020-03-26 |
| IL267503A (en) | 2019-08-29 |
| MA47074A (fr) | 2021-04-14 |
| AU2017379245A1 (en) | 2019-07-11 |
| CA3047426A1 (en) | 2018-06-28 |
| WO2018114501A1 (de) | 2018-06-28 |
| ECSP19044577A (es) | 2019-06-30 |
| JP2020502215A (ja) | 2020-01-23 |
| TW201834653A (zh) | 2018-10-01 |
| PE20191240A1 (es) | 2019-09-16 |
| EP3558380A1 (de) | 2019-10-30 |
| KR20190099245A (ko) | 2019-08-26 |
| UY37541A (es) | 2018-07-31 |
| CU20190063A7 (es) | 2020-02-04 |
| CL2019001726A1 (es) | 2019-11-29 |
| JOP20190148A1 (ar) | 2019-06-18 |
| BR112019012836A2 (pt) | 2019-12-17 |
| PH12019501458A1 (en) | 2020-06-01 |
| CO2019006642A2 (es) | 2019-09-18 |
| MX2019007619A (es) | 2019-09-06 |
| CN110290809A (zh) | 2019-09-27 |
| DOP2019000172A (es) | 2019-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190300A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| CR20190299A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de transtornos respiratorios | |
| ECSP18043573A (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño | |
| CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
| DOP2021000105A (es) | Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task1 y task3 y su uso para la terapia de trastornos respiratorios | |
| AR110417A1 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| EA201991540A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания | |
| EA201991538A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания |